Laboratory of Immunobiology
Federal University of Santa Catarina
Florianópolis - Brazil
We employ state-of-art basic science to design and develop better vaccines against serious human threats.
We aim to develop peptide-based vaccines against the following major human diseases:
Additionally, we develop tools for studying gene functions and to reveal novel therapeutic strategies.
Here are some of the tools in development:
Genome editing by CRISPR
Nanotechnology delivery systems
Immuno-based assays for tuberculosis
Silva HM et al Vasculature-associated fat macrophages readily adapt to inflammatory and metabolic challenges. J Exp Med. 2019 Apr 1;216(4):786-806
Antunes KH et al. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. Nat Commun. 2019;10(1):3273.
Dos Santos PF, Van Weyenbergh J, Delgobo M, et al. ISG15-Induced IL-10 Is a Novel Anti-Inflammatory Myeloid Axis Disrupted during Active Tuberculosis. J Immunol. 2018;200(4):1434-1442. doi:10.4049/jimmunol.1701120
Fazolo T, Gassen RB, de Freitas DN, et al. Vaccination with RSV M209-223 peptide promotes a protective immune response associated with reduced pulmonary inflammation. Antiviral Res. 2018;157:102-110.
Fleith RC, Lobo FP, Dos Santos PF, et al. Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans. Sci Rep. 2016;6:36339.
de Faria TJ, Roman M, de Souza NM, et al. An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob Agents Chemother. 2012;56(5):2259-2267.
Nogueira L, Cardoso FC, Mattos AM, et al. Mycobacterium tuberculosis Rv1419 encodes a secreted 13 kDa lectin with immunological reactivity during human tuberculosis. Eur J Immunol. 2010;40(3):744-753.